Adis International Inc

Summary

Organization: Adis International Inc
Country: USA

Top Publications

  1. ncbi Spotlight on ranolazine in chronic stable angina pectoris
    M Asif A Siddiqui
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 6:357-9. 2006
  2. ncbi Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:827-58. 2005
  3. ncbi Spotlight on cefditoren pivoxil in bacterial infections
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:149-52. 2005
  4. ncbi Lucinactant: in neonatal respiratory distress syndrome
    Marit D Moen
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:139-45; discussion 146-7. 2005
  5. ncbi Efalizumab
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:113-8; discussion 119-20. 2005
  6. ncbi Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women
    Monique P Curran
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:127-9. 2002
  7. ncbi Spotlight on insulin glargine in type 1 and 2 diabetes mellitus
    Kate McKeage
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:55-8. 2002
  8. ncbi The Novolizer: a multidose dry powder inhaler
    M Asif A Siddiqui
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, PA 19067, USA
    Treat Respir Med 4:63-9. 2005
  9. ncbi Pimecrolimus: a review of its use in atopic dermatitis
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:479-95. 2004
  10. ncbi Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris
    Caroline Fenton
    Adis International Limited, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:463-78. 2004

Scientific Experts

  • Paul L McCormack
  • C Lucioni
  • Keri Wellington
  • Caroline M Perry
  • Lesley J Scott
  • Antona J Wagstaff
  • John Waugh
  • M Asif A Siddiqui
  • Monique P Curran
  • Dean M Robinson
  • Dene Simpson
  • Karen L Goa
  • Susan M Cheer
  • Stuart Noble
  • Susan J Keam
  • Katherine A Lyseng-Williamson
  • Toni M Dando
  • Gillian M Keating
  • Caroline Fenton
  • Greg L Plosker
  • David P Figgitt
  • Therese M Chapman
  • Blair Jarvis
  • Gregory T Warner
  • Vicki Oldfield
  • Neil A Reynolds
  • David R Goldsmith
  • Marit D Moen
  • Stephanie E Easthope
  • Tracey Wright
  • Ngaire J White
  • Tim Ibbotson
  • Lynne Bang
  • James Frampton
  • Nila Bhana
  • Kate McKeage
  • Richard B R Muijsers
  • Amitabh Prakash
  • Miriam Sharpe
  • Douglas Ormrod
  • S E Easthope
  • E B Melian
  • C J Dunn
  • B Jarvis
  • Jean Pierre Zellweger
  • Daniel E Hilleman
  • Antona Wagstaff
  • Jane K McGavin
  • Karen Goa
  • Adam McGechan
  • K L Goa
  • C M Spencer

Detail Information

Publications62

  1. ncbi Spotlight on ranolazine in chronic stable angina pectoris
    M Asif A Siddiqui
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 6:357-9. 2006
    ..Nevertheless, ranolazine ER may well prove to be a useful alternative and adjunct to conventional hemodynamic antianginal therapy in the treatment of chronic stable angina...
  2. ncbi Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions
    Dene Simpson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:827-58. 2005
    ....
  3. ncbi Spotlight on cefditoren pivoxil in bacterial infections
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:149-52. 2005
    ....
  4. ncbi Lucinactant: in neonatal respiratory distress syndrome
    Marit D Moen
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:139-45; discussion 146-7. 2005
    ..Adverse events were transient and related to the administration procedure. There were no differences in the incidences of complications of prematurity between lucinactant and the other surfactants...
  5. ncbi Efalizumab
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 6:113-8; discussion 119-20. 2005
    ....
  6. ncbi Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women
    Monique P Curran
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:127-9. 2002
    ..In the meantime, continuous oral estradiol plus intermittent oral norgestimate can be regarded as an effective new option for HRT in postmenopausal women...
  7. ncbi Spotlight on insulin glargine in type 1 and 2 diabetes mellitus
    Kate McKeage
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 1:55-8. 2002
    ..Therefore, insulin glargine is likely to be a useful addition to the armamentarium of insulin therapy by establishing basal glycemic control with once daily administration and a reduced risk of nocturnal hypoglycemia...
  8. ncbi The Novolizer: a multidose dry powder inhaler
    M Asif A Siddiqui
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, PA 19067, USA
    Treat Respir Med 4:63-9. 2005
    ..Overall, the Novolizer was well accepted, with an improved compliance in 80% of patients that was attributable to the control mechanisms of the device...
  9. ncbi Pimecrolimus: a review of its use in atopic dermatitis
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:479-95. 2004
    ..Thus, topical pimecrolimus 1% cream is an effective treatment option for the management of mild-to-moderate atopic dermatitis...
  10. ncbi Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris
    Caroline Fenton
    Adis International Limited, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:463-78. 2004
    ..The safety of calcipotriol/betamethasone dipropionate in patients treated for up to 1 year was generally good; fewer than 5% of patients experienced adverse events possibly associated with long-term corticosteroid use...
  11. ncbi Spotlight on adapalene in acne vulgaris
    John Waugh
    Adis International Inc, Yardley, PA 19067, USA
    Am J Clin Dermatol 5:369-71. 2004
    ..These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris...
  12. ncbi Poly-L-lactic acid
    Caroline M Perry
    Adis International Inc Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:361-6; discussion 367-8. 2004
    ..Poly-L-lactic acid was generally well tolerated. No serious adverse events were reported...
  13. ncbi Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation
    Antona J Wagstaff
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 3:327-32. 2004
    ..Like the IR formulation, metformin XT is generally well tolerated; gastro-intestinal adverse events are, however, common...
  14. ncbi 17 beta-estradiol/levonorgestrel transdermal system
    Toni M Dando
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 3:319-24. 2004
    ..The estradiol/levonorgestrel transdermal system was generally well tolerated. In two trials, application-site reactions were common in all treatment groups (estradiol/levonorgestrel, estradiol, and placebo)...
  15. ncbi Spotlight on rosiglitazone in the management of type 2 diabetes mellitus
    Antona J Wagstaff
    Adis International Inc, Langhorne, Pennsylvania, USA
    Treat Endocrinol 1:411-4. 2002
    ..Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus...
  16. ncbi Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive
    Susan J Keam
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Treat Endocrinol 2:49-70. 2003
    ..A similar improvement in skin condition (acne, seborrhea) was observed in women receiving EE/DRSP or ethinylestradiol 35microg/cyproterone acetate 2mg in a randomized, double-blind trial...
  17. ncbi Spotlight on paricalcitol in secondary hyperparathyroidism
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Endocrinol 4:185-6. 2005
    ..Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure...
  18. ncbi Reteplase: a review of its use in the management of thrombotic occlusive disorders
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:265-85. 2006
    ....
  19. ncbi Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis
    Vicki Oldfield
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 6:189-208. 2006
    ..Thus, in accordance with current clinical guidelines, bosentan is a convenient, effective, and generally well tolerated agent for use in the first-line treatment of class III PAH or second-line treatment of class IV PAH...
  20. ncbi Rotavirus vaccine (RotaTeq)
    Gillian M Keating
    Adis International Inc, Yardley, PA 19067, USA
    Paediatr Drugs 8:197-202; discussion 203-4. 2006
    ..Rotavirus vaccine and placebo were associated with serious adverse events in <3% of infants in either group...
  21. ncbi T-SPOT.TB: an in vitro diagnostic assay measuring T-cell reaction to Mycobacterium tuberculosis-specific antigens
    Antona J Wagstaff
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Mol Diagn Ther 10:57-63; discussion 64-5. 2006
    ..Unlike the TST, the RD1 ELISPOT assay is not confounded by bacille Calmette-Guérin vaccination...
  22. ncbi Spotlight on etanercept in plaque psoriasis and psoriatic arthritis
    David R Goldsmith
    Adis International Inc, 770 Township Line Road, Suite 300, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:401-3. 2005
    ....
  23. ncbi Once-monthly ibandronate
    Toni M Dando
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 4:381-7; discussion 389-90. 2005
    ..Significantly more women with osteoporosis preferred once-monthly ibandronate and found it more convenient than once-weekly alendronate, according to data from a 6-month, randomized, open-label, crossover study...
  24. ncbi Alendronate/colecalciferol
    Neil A Reynolds
    Adis International Inc, Yardley, Pennsylvania, USA
    Treat Endocrinol 4:371-7; discussion 379. 2005
    ..The treatment-related adverse event profile of once-weekly alendronate/colecalciferol 70 mg/2800 IU was similar to that of once-weekly alendronate in the 15-week, double-blind study in patients with osteoporosis...
  25. ncbi Darbepoetin alfa: its use in anemia associated with chronic kidney disease
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:327-43. 2005
    ....
  26. ncbi Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism
    Dean M Robinson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 5:335-46. 2005
    ..It thus provides a valuable alternative to UFH and low-molecular weight heparins in the treatment of acute VTE, particularly in the outpatient setting...
  27. ncbi Clofarabine: in pediatric patients with acute lymphoblastic leukemia
    Monique P Curran
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 7:259-64; discussion 265-6. 2005
    ..Capillary leak syndrome or systemic inflammatory response syndrome was reported in four patients...
  28. ncbi Ipratropium bromide HFA
    Keri Wellington
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Treat Respir Med 4:215-20; discussion 221-2. 2005
    ..The most common adverse events were related to respiratory system disorders. During the 1-year study, dry mouth was reported by 1.3% and 0.7% of patients in the ipratropium bromide HFA or ipratropium bromide CFC groups...
  29. ncbi Anakinra: a review of its use in the management of rheumatoid arthritis
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    BioDrugs 19:189-202. 2005
    ..It is subcutaneously administered and is generally well tolerated. Anakinra offers a useful addition to the range of drugs available for the treatment of RA...
  30. ncbi Risedronate once a week
    Ngaire J White
    Adis International Inc, Yardley, Pennsylvania, 19067, USA
    Treat Endocrinol 2:415-20; discussion 421. 2003
    ..The tolerability profile (including the incidence of upper gastrointestinal adverse events) of risedronate 35mg once a week in women with postmenopausal osteoporosis, was similar to that of risedronate 5mg once daily...
  31. ncbi The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 4:257-68. 2004
    ..The group receiving insulin was too small to draw meaningful conclusions...
  32. ncbi Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection
    Caroline Fenton
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 6:177-97. 2004
    ..The use of palivizumab in these other high-risk populations is likely to be determined as much by pharmacoeconomic considerations as by efficacy outcomes...
  33. ncbi Breast cancer: new technologies for risk assessment and diagnosis
    Tracey Wright
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Mol Diagn 7:49-55. 2003
    ..Both are enhancements of older thermal imaging technology based on the principle that heat equates to unwanted activity, in the case of breast cancer, abnormal cell proliferation...
  34. ncbi Oxcarbazepine: a review of its use in children with epilepsy
    Lynne Bang
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:557-73. 2003
    ..Nevertheless, the generally favorable tolerability profile and relatively low potential for drug interactions of oxcarbazepine make it a valuable option in the treatment of childhood epilepsy...
  35. ncbi Linezolid: in infants and children with severe Gram-positive infections
    Katherine A Lyseng-Williamson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:419-29; discussion 430-1. 2003
    ..Linezolid is generally well tolerated. The most common drug-related adverse events in the comparator-controlled trials were diarrhea, nausea, and headache; most events were mild to moderate in severity...
  36. ncbi Atomoxetine
    Dene Simpson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Paediatr Drugs 5:407-15; discussion 416-7. 2003
    ..The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled substance in the US...
  37. ncbi Memantine
    Blair Jarvis
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 20:465-76; discussion 477-8. 2003
    ..Adverse events (incidence in memantine recipients greater than in placebo recipients) occurring in patients with moderately severe to severe dementia included diarrhoea, insomnia, dizziness, headache and hallucination...
  38. ncbi Alefacept
    James Frampton
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 4:277-86; discussion 287. 2003
    ..No opportunistic infections have been reported, nor is there evidence of an increased risk of malignancies...
  39. ncbi Formoterol delivered by Turbuhaler: in pediatric asthma
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 5:63-8; discussion 69. 2003
    ..Formoterol delivered by Turbuhaler was well tolerated in pediatric patients, with respiratory infection being the most commonly reported adverse event...
  40. ncbi Lansoprazole: in the management of gastroesophageal reflux disease in children
    Lesley J Scott
    Adis International Inc, Langhorne, Pennsylvania 10947, USA
    Paediatr Drugs 5:57-61; discussion 62. 2003
    ..The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache...
  41. ncbi [Economic evaluation of vaccination programs in adults]
    C Lucioni
    Adis International, Milano
    Ann Ig 14:69-73. 2002
  42. ncbi Lamivudine: in children and adolescents with chronic hepatitis B virus infection
    Susan J Keam
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Paediatr Drugs 4:687-94; discussion 695-6. 2002
    ..Oral lamivudine is generally well tolerated by children and adolescents with chronic hepatitis B, with a similar tolerability profile to placebo at the recommended once daily dosage of 3 mg/kg up to a maximum of 100 mg/day...
  43. ncbi Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection
    Nila Bhana
    Adis International Inc, 860 Town Center Drive, Langhorne, PA 19047, USA
    Paediatr Drugs 4:515-53. 2002
    ..Zidovudine was generally well tolerated as monotherapy in clinical trials of pediatric patients with HIV infection, and adverse events were similar to those reported in adults, with anemia and neutropenia being the most common...
  44. ncbi Spotlight on topical pimecrolimus in atopic dermatitis
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 3:435-8. 2002
    ..Topical pimecrolimus 1.0% provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis...
  45. ncbi Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne
    Gregory T Warner
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Clin Dermatol 3:349-60. 2002
    ..The most common adverse events were dry skin, peeling, erythema and rash; however, adverse event-caused treatment discontinuation rates for patients using clindamycin/benzoyl peroxide were low, ranging from 0 to 0.8%...
  46. ncbi Cefepime: a review of its use in the management of hospitalized patients with pneumonia
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19407, USA
    Am J Respir Med 2:75-107. 2003
    ..Other, less common, adverse events included pruritus, urticaria, nausea, vomiting oral candidiasis, colitis, headache, fever, erythema and vaginitis...
  47. ncbi Flunisolide HFA
    John Waugh
    Adis International Inc, Langhorne, Pennsylvannia 19047, USA
    Am J Respir Med 1:369-72; discussion 373. 2002
    ..Flunisolide HFA was well tolerated in all trials. A long-term study found no suppression of adrenal function and minimal systemic effects were observed both in adults and children...
  48. ncbi Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease
    Katherine A Lyseng-Williamson
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:273-82; discussion 283-4. 2002
    ..Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD...
  49. ncbi Topical methyl aminolevulinate
    M Asif A Siddiqui
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Clin Dermatol 5:127-37; discussion 138-40. 2004
    ..The most frequently reported adverse events were local phototoxicity reactions, most of which were of mild to moderate intensity, resolved rapidly and were rarely treatment limiting...
  50. ncbi Rosuvastatin: a review of its use in the management of dyslipidemia
    Lesley J Scott
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 4:117-38. 2004
    ..Thus, rosuvastatin has emerged as a valuable choice for first-line treatment in the management of low- to high-risk patients requiring lipid-lowering drug therapy...
  51. ncbi Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization
    Tim Ibbotson
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 3:381-6. 2003
    ....
  52. ncbi Losartan: in the reduction of stroke risk in patients with hypertension and left ventricular hypertrophy
    John Waugh
    Adis International Inc, Yardley, Pennsylvania 19067, USA
    Am J Cardiovasc Drugs 3:371-7; discussion 378-9. 2003
    ..Significantly fewer losartan than atenolol recipients discontinued treatment because of adverse events, drug-related adverse events, or serious, drug-related adverse events...
  53. ncbi Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction
    C J Dunn
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Cardiovasc Drugs 1:51-66. 2001
    ..94 and 1.66%, respectively). The rate of noncerebral bleeding was lower with tenecteplase than with alteplase (26.43 vs 28.95%; p = 0.0003). No causal link has been demonstrated between tenecteplase and allergic reactions in patients...
  54. ncbi Clopidogrel: potential in the prevention of cardiovascular events in patients with acute coronary syndromes
    S E Easthope
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 1:467-74; discussion 475-6. 2001
    ..However, there was no difference between the two groups in the incidence of bleeding episodes that were considered to be life-threatening...
  55. ncbi Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels
    Miriam Sharpe
    Adis International Limited, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:125-32; discussion 133-4. 2002
    ..In double-blind, placebo-controlled trials in a total of 804 patients, the pooled incidences of individual adverse events were generally similar with fenofibrate and placebo...
  56. ncbi Valsartan: in chronic heart failure
    Keri Wellington
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:267-74; discussion 275-6. 2002
    ..The most common adverse events in the valsartan and placebo groups which led to discontinuation of treatment were dizziness, renal impairment (both of which occurred in significantly more valsartan recipients) and hypotension...
  57. ncbi Bosentan
    Amitabh Prakash
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 2:335-43; discussion 343. 2002
    ..Those that occurred less frequently with bosentan 125 mg twice daily than with placebo included dizziness, worsening of symptoms of pulmonary arterial hypertension, cough and dyspnea...
  58. ncbi Cilostazol: a review of its use in intermittent claudication
    Therese M Chapman
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Cardiovasc Drugs 3:117-38. 2003
    ..Coadministration of cilostazol with aspirin or warfarin did not result in any clinically significant changes to coagulation parameters, bleeding time or platelet aggregation...
  59. ncbi Spotlight on zanamivir in influenza
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:147-52. 2002
    ..Zanamivir shows potential for prophylaxis in persons for whom vaccination is contraindicated or ineffective, in elderly or high-risk patients in long-term care facilities and in households...
  60. ncbi Spotlight on montelukast in asthma in children 2 to 14 years of age
    Richard B R Muijsers
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:225-8. 2002
    ..Montelukast is generally well tolerated. The frequency of adverse events in montelukast-treated children of all ages was comparable to that in patients receiving placebo...
  61. ncbi Formoterol: a review of its use in chronic obstructive pulmonary disease
    Susan M Cheer
    Adis International Inc, Langhorne, Pennsylvania 19047, USA
    Am J Respir Med 1:285-300. 2002
    ..Thus, inhaled formoterol may be considered as a first-line option for the management of bronchoconstriction in patients with COPD who require regular bronchodilator therapy for the management of symptoms...
  62. ncbi Clobetasol propionate foam, 0.05%
    E B Melian
    Adis International Inc, Langhorne, Pennsylvania, USA
    Am J Clin Dermatol 2:89-92; discussion 93. 2001
    ..Clobetasol foam 7 g/day for 2 weeks induced reversible suppression of the hypothalamic-pituitary-adrenal axis in 3 out of 13 patients (methodology of assessment not provided)...